Sunitinib in pancreatic neuroendocrine tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-06-02

AUTHORS

Eric Raymond, Pascal Hammel, Chantal Dreyer, Christian Maatescu, Olivia Hentic, Philippe Ruszniewski, Sandrine Faivre

ABSTRACT

AsbtractSunitinib is an oral multitarget tyrosine kinase inhibitor with potent antiangiogenic properties. Preclinical data have demonstrated that pancreatic neuroendocrine tumors depend on vascular endothelial growth factor receptors and platelet growth factor receptors-signaling pathways for tumor angiogenesis. Sunitinib has recently been approved for the treatment of patients with advanced, progressive pancreatic neuroendocrine tumors. Sunitinib has demonstrated clinically meaningful improvements in progression-free survival in a double-blinded randomized trial against placebo, setting progression-free survival as a valid endpoint for the evaluation of novel agents in patients with pancreatic neuroendocrine tumors. Although patients who progressed in this phase III trial were allowed to cross-over, a trend toward improvement in overall survival was also observed. In this trial, side effects reported with sunitinib were those previously reported in other tumor types, including hand–foot syndrome, diarrhea, and hypertension. This trial also investigated patient-reported outcome and showed that treatment with sunitinib did not affect quality of life of patient. Interestingly, this trial showed that sunitinib could be combined with somatostatin analogues without affecting the safety profile of either sunitinib or somatostatin analogues. Since the overall survival of patients with well-differentiated neuroendocrine tumors remains sufficiently long, it is worth considering using alternate sequences of targeted therapy (such as everolimus) and chemotherapy to optimize the care of patients with advanced diseases. The optimal sequence for using chemotherapy, everolimus, and sunitinib will remain to be established in clinical trials. More... »

PAGES

117-125

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-012-0220-2

DOI

http://dx.doi.org/10.1007/s11523-012-0220-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051641701

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22661319


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raymond", 
        "givenName": "Eric", 
        "id": "sg:person.0722574726.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hammel", 
        "givenName": "Pascal", 
        "id": "sg:person.01355345644.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dreyer", 
        "givenName": "Chantal", 
        "id": "sg:person.01047617457.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047617457.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maatescu", 
        "givenName": "Christian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hentic", 
        "givenName": "Olivia", 
        "id": "sg:person.0736275266.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736275266.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruszniewski", 
        "givenName": "Philippe", 
        "id": "sg:person.0640551545.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology (INSERM U728\u2013Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du G\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre", 
        "givenName": "Sandrine", 
        "id": "sg:person.01026352014.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrd2380", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044070644", 
          "https://doi.org/10.1038/nrd2380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012438597", 
          "https://doi.org/10.1038/sj.bjc.6602245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005779365", 
          "https://doi.org/10.1038/sj.bjc.6605618"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/471316a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020489256", 
          "https://doi.org/10.1038/471316a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2009.110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030167380", 
          "https://doi.org/10.1038/nrclinonc.2009.110"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/315115a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034094925", 
          "https://doi.org/10.1038/315115a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35036374", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049517272", 
          "https://doi.org/10.1038/35036374"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06-02", 
    "datePublishedReg": "2012-06-02", 
    "description": "AsbtractSunitinib is an oral multitarget tyrosine kinase inhibitor with potent antiangiogenic properties. Preclinical data have demonstrated that pancreatic neuroendocrine tumors depend on vascular endothelial growth factor receptors and platelet growth factor receptors-signaling pathways for tumor angiogenesis. Sunitinib has recently been approved for the treatment of patients with advanced, progressive pancreatic neuroendocrine tumors. Sunitinib has demonstrated clinically meaningful improvements in progression-free survival in a double-blinded randomized trial against placebo, setting progression-free survival as a valid endpoint for the evaluation of novel agents in patients with pancreatic neuroendocrine tumors. Although patients who progressed in this phase III trial were allowed to cross-over, a trend toward improvement in overall survival was also observed. In this trial, side effects reported with sunitinib were those previously reported in other tumor types, including hand\u2013foot syndrome, diarrhea, and hypertension. This trial also investigated patient-reported outcome and showed that treatment with sunitinib did not affect quality of life of patient. Interestingly, this trial showed that sunitinib could be combined with somatostatin analogues without affecting the safety profile of either sunitinib or somatostatin analogues. Since the overall survival of patients with well-differentiated neuroendocrine tumors remains sufficiently long, it is worth considering using alternate sequences of targeted therapy (such as everolimus) and chemotherapy to optimize the care of patients with advanced diseases. The optimal sequence for using chemotherapy, everolimus, and sunitinib will remain to be established in clinical trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11523-012-0220-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "pancreatic neuroendocrine tumors", 
      "progression-free survival", 
      "neuroendocrine tumors", 
      "overall survival", 
      "somatostatin analogues", 
      "oral multitarget tyrosine kinase inhibitor", 
      "progressive pancreatic neuroendocrine tumors", 
      "multitarget tyrosine kinase inhibitor", 
      "vascular endothelial growth factor receptor", 
      "hand-foot syndrome", 
      "phase III trials", 
      "endothelial growth factor receptor", 
      "treatment of patients", 
      "patient-reported outcomes", 
      "care of patients", 
      "tyrosine kinase inhibitors", 
      "quality of life", 
      "potent antiangiogenic properties", 
      "receptor-signaling pathway", 
      "growth factor receptor", 
      "III trials", 
      "advanced disease", 
      "safety profile", 
      "preclinical data", 
      "valid endpoint", 
      "clinical trials", 
      "novel agents", 
      "sunitinib", 
      "side effects", 
      "patients", 
      "tumor types", 
      "meaningful improvements", 
      "antiangiogenic properties", 
      "tumor angiogenesis", 
      "tumors", 
      "trials", 
      "kinase inhibitors", 
      "factor receptor", 
      "survival", 
      "chemotherapy", 
      "treatment", 
      "placebo", 
      "hypertension", 
      "everolimus", 
      "diarrhea", 
      "syndrome", 
      "therapy", 
      "disease", 
      "endpoint", 
      "receptors", 
      "care", 
      "angiogenesis", 
      "outcomes", 
      "inhibitors", 
      "improvement", 
      "agents", 
      "pathway", 
      "analogues", 
      "evaluation", 
      "life", 
      "alternate sequence", 
      "effect", 
      "profile", 
      "optimal sequence", 
      "data", 
      "quality", 
      "types", 
      "trends", 
      "sequence", 
      "properties", 
      "AsbtractSunitinib", 
      "platelet growth factor receptors-signaling pathways", 
      "growth factor receptors-signaling pathways", 
      "factor receptors-signaling pathways"
    ], 
    "name": "Sunitinib in pancreatic neuroendocrine tumors", 
    "pagination": "117-125", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051641701"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-012-0220-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22661319"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-012-0220-2", 
      "https://app.dimensions.ai/details/publication/pub.1051641701"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_579.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11523-012-0220-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0220-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0220-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0220-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0220-2'


 

This table displays all metadata directly associated to this object as RDF triples.

243 TRIPLES      22 PREDICATES      116 URIs      101 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-012-0220-2 schema:about N1399373e82a34eef904beac41d36afd8
2 N15c0dd14305642f0a47ae1ee1f5ebc65
3 N191a8ad394ea4cce9260e74e92c37465
4 N384343ba30a44331938b45aadbbf81e9
5 N39d0f3d97da24c12849ac3f8f3986225
6 N48016af257124aa8951afa7f063aa94b
7 N6f62771769024490bf5a8047aed9e06f
8 Nb127052053e2409faab3b3203433a2e3
9 Ndf3c83c6d83b42bdbbda89c519eafb14
10 anzsrc-for:11
11 anzsrc-for:1112
12 schema:author N66c044ad60bf4f6595487056700920e0
13 schema:citation sg:pub.10.1038/315115a0
14 sg:pub.10.1038/35036374
15 sg:pub.10.1038/471316a
16 sg:pub.10.1038/nrclinonc.2009.110
17 sg:pub.10.1038/nrd2380
18 sg:pub.10.1038/sj.bjc.6602245
19 sg:pub.10.1038/sj.bjc.6605618
20 schema:datePublished 2012-06-02
21 schema:datePublishedReg 2012-06-02
22 schema:description AsbtractSunitinib is an oral multitarget tyrosine kinase inhibitor with potent antiangiogenic properties. Preclinical data have demonstrated that pancreatic neuroendocrine tumors depend on vascular endothelial growth factor receptors and platelet growth factor receptors-signaling pathways for tumor angiogenesis. Sunitinib has recently been approved for the treatment of patients with advanced, progressive pancreatic neuroendocrine tumors. Sunitinib has demonstrated clinically meaningful improvements in progression-free survival in a double-blinded randomized trial against placebo, setting progression-free survival as a valid endpoint for the evaluation of novel agents in patients with pancreatic neuroendocrine tumors. Although patients who progressed in this phase III trial were allowed to cross-over, a trend toward improvement in overall survival was also observed. In this trial, side effects reported with sunitinib were those previously reported in other tumor types, including hand–foot syndrome, diarrhea, and hypertension. This trial also investigated patient-reported outcome and showed that treatment with sunitinib did not affect quality of life of patient. Interestingly, this trial showed that sunitinib could be combined with somatostatin analogues without affecting the safety profile of either sunitinib or somatostatin analogues. Since the overall survival of patients with well-differentiated neuroendocrine tumors remains sufficiently long, it is worth considering using alternate sequences of targeted therapy (such as everolimus) and chemotherapy to optimize the care of patients with advanced diseases. The optimal sequence for using chemotherapy, everolimus, and sunitinib will remain to be established in clinical trials.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N703a672884204638bf0c56c8a3a4942c
27 Ncd73bd9c351340e79deeab9b0bd6af67
28 sg:journal.1036678
29 schema:keywords AsbtractSunitinib
30 III trials
31 advanced disease
32 agents
33 alternate sequence
34 analogues
35 angiogenesis
36 antiangiogenic properties
37 care
38 care of patients
39 chemotherapy
40 clinical trials
41 data
42 diarrhea
43 disease
44 effect
45 endothelial growth factor receptor
46 endpoint
47 evaluation
48 everolimus
49 factor receptor
50 factor receptors-signaling pathways
51 growth factor receptor
52 growth factor receptors-signaling pathways
53 hand-foot syndrome
54 hypertension
55 improvement
56 inhibitors
57 kinase inhibitors
58 life
59 meaningful improvements
60 multitarget tyrosine kinase inhibitor
61 neuroendocrine tumors
62 novel agents
63 optimal sequence
64 oral multitarget tyrosine kinase inhibitor
65 outcomes
66 overall survival
67 pancreatic neuroendocrine tumors
68 pathway
69 patient-reported outcomes
70 patients
71 phase III trials
72 placebo
73 platelet growth factor receptors-signaling pathways
74 potent antiangiogenic properties
75 preclinical data
76 profile
77 progression-free survival
78 progressive pancreatic neuroendocrine tumors
79 properties
80 quality
81 quality of life
82 receptor-signaling pathway
83 receptors
84 safety profile
85 sequence
86 side effects
87 somatostatin analogues
88 sunitinib
89 survival
90 syndrome
91 therapy
92 treatment
93 treatment of patients
94 trends
95 trials
96 tumor angiogenesis
97 tumor types
98 tumors
99 types
100 tyrosine kinase inhibitors
101 valid endpoint
102 vascular endothelial growth factor receptor
103 schema:name Sunitinib in pancreatic neuroendocrine tumors
104 schema:pagination 117-125
105 schema:productId N1372a25c6b074330be89054a857719ba
106 N553940bdbc6c4529a6d96506eb14a569
107 N59ce8d53dced452c8be2bcb76a8dec8e
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051641701
109 https://doi.org/10.1007/s11523-012-0220-2
110 schema:sdDatePublished 2021-12-01T19:28
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N38c0c8db904849d8bc6f79a1ad2875fb
113 schema:url https://doi.org/10.1007/s11523-012-0220-2
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N1004408d249845a1953beb66fbd4087e rdf:first sg:person.0640551545.21
118 rdf:rest Nda7be643da7f4d3ba8917770e803b007
119 N1372a25c6b074330be89054a857719ba schema:name dimensions_id
120 schema:value pub.1051641701
121 rdf:type schema:PropertyValue
122 N1399373e82a34eef904beac41d36afd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Sunitinib
124 rdf:type schema:DefinedTerm
125 N15c0dd14305642f0a47ae1ee1f5ebc65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 N191a8ad394ea4cce9260e74e92c37465 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Neuroendocrine Tumors
130 rdf:type schema:DefinedTerm
131 N26e3d34eac1041858bfb192453e663dd rdf:first sg:person.0736275266.26
132 rdf:rest N1004408d249845a1953beb66fbd4087e
133 N3211ba56eb56483a868336a47b2bbb42 rdf:first Nbb352705421744509aa942413435d753
134 rdf:rest N26e3d34eac1041858bfb192453e663dd
135 N384343ba30a44331938b45aadbbf81e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Pancreatic Neoplasms
137 rdf:type schema:DefinedTerm
138 N38c0c8db904849d8bc6f79a1ad2875fb schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 N39d0f3d97da24c12849ac3f8f3986225 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Pyrroles
142 rdf:type schema:DefinedTerm
143 N48016af257124aa8951afa7f063aa94b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Angiogenesis Inhibitors
145 rdf:type schema:DefinedTerm
146 N553940bdbc6c4529a6d96506eb14a569 schema:name doi
147 schema:value 10.1007/s11523-012-0220-2
148 rdf:type schema:PropertyValue
149 N59ce8d53dced452c8be2bcb76a8dec8e schema:name pubmed_id
150 schema:value 22661319
151 rdf:type schema:PropertyValue
152 N66c044ad60bf4f6595487056700920e0 rdf:first sg:person.0722574726.55
153 rdf:rest Nba7680a942f844b98c7c9009c7be6a89
154 N6f62771769024490bf5a8047aed9e06f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Indoles
156 rdf:type schema:DefinedTerm
157 N703a672884204638bf0c56c8a3a4942c schema:issueNumber 2
158 rdf:type schema:PublicationIssue
159 Nb127052053e2409faab3b3203433a2e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Animals
161 rdf:type schema:DefinedTerm
162 Nb66124c827324a50addaa6736616a49e rdf:first sg:person.01047617457.40
163 rdf:rest N3211ba56eb56483a868336a47b2bbb42
164 Nba7680a942f844b98c7c9009c7be6a89 rdf:first sg:person.01355345644.55
165 rdf:rest Nb66124c827324a50addaa6736616a49e
166 Nbb352705421744509aa942413435d753 schema:affiliation grid-institutes:grid.411599.1
167 schema:familyName Maatescu
168 schema:givenName Christian
169 rdf:type schema:Person
170 Ncd73bd9c351340e79deeab9b0bd6af67 schema:volumeNumber 7
171 rdf:type schema:PublicationVolume
172 Nda7be643da7f4d3ba8917770e803b007 rdf:first sg:person.01026352014.76
173 rdf:rest rdf:nil
174 Ndf3c83c6d83b42bdbbda89c519eafb14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Antineoplastic Agents
176 rdf:type schema:DefinedTerm
177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
178 schema:name Medical and Health Sciences
179 rdf:type schema:DefinedTerm
180 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
181 schema:name Oncology and Carcinogenesis
182 rdf:type schema:DefinedTerm
183 sg:journal.1036678 schema:issn 1776-2596
184 1776-260X
185 schema:name Targeted Oncology
186 schema:publisher Springer Nature
187 rdf:type schema:Periodical
188 sg:person.01026352014.76 schema:affiliation grid-institutes:grid.411599.1
189 schema:familyName Faivre
190 schema:givenName Sandrine
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76
192 rdf:type schema:Person
193 sg:person.01047617457.40 schema:affiliation grid-institutes:grid.411599.1
194 schema:familyName Dreyer
195 schema:givenName Chantal
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047617457.40
197 rdf:type schema:Person
198 sg:person.01355345644.55 schema:affiliation grid-institutes:grid.411599.1
199 schema:familyName Hammel
200 schema:givenName Pascal
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55
202 rdf:type schema:Person
203 sg:person.0640551545.21 schema:affiliation grid-institutes:grid.411599.1
204 schema:familyName Ruszniewski
205 schema:givenName Philippe
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21
207 rdf:type schema:Person
208 sg:person.0722574726.55 schema:affiliation grid-institutes:grid.411599.1
209 schema:familyName Raymond
210 schema:givenName Eric
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55
212 rdf:type schema:Person
213 sg:person.0736275266.26 schema:affiliation grid-institutes:grid.411599.1
214 schema:familyName Hentic
215 schema:givenName Olivia
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736275266.26
217 rdf:type schema:Person
218 sg:pub.10.1038/315115a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034094925
219 https://doi.org/10.1038/315115a0
220 rdf:type schema:CreativeWork
221 sg:pub.10.1038/35036374 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049517272
222 https://doi.org/10.1038/35036374
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/471316a schema:sameAs https://app.dimensions.ai/details/publication/pub.1020489256
225 https://doi.org/10.1038/471316a
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nrclinonc.2009.110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030167380
228 https://doi.org/10.1038/nrclinonc.2009.110
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/nrd2380 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044070644
231 https://doi.org/10.1038/nrd2380
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/sj.bjc.6602245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012438597
234 https://doi.org/10.1038/sj.bjc.6602245
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/sj.bjc.6605618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005779365
237 https://doi.org/10.1038/sj.bjc.6605618
238 rdf:type schema:CreativeWork
239 grid-institutes:grid.411599.1 schema:alternateName Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du Général Leclerc, 92110, Clichy, France
240 Department of Medical Oncology (INSERM U728–Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du Général Leclerc, 92110, Clichy, France
241 schema:name Department of Gastro-entero-pancreatology, Beaujon University Hospital, 100 boulevard du Général Leclerc, 92110, Clichy, France
242 Department of Medical Oncology (INSERM U728–Paris 7 Diderot University), Beaujon University Hospital, 100 boulevard du Général Leclerc, 92110, Clichy, France
243 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...